Stem cells have the power to regenerate tissues throughout the body
Experienced scientific management team with a past record of senior positions in the pharma industry, in companies such as Teva, Gamida Cell, Pluristem, CollPlant, Dexcel, Trima. Team members hold advanced degrees from top universities and research institutes in the US and in Israel including Harvard, the University of Illinois Chicago, Weizmann Institute of Science, Beer Sheva and Hebrew University.
Mr. Marom received his BSc in Chemical Engineering from the Technion – Israel Institute of Technology with distinction. He brings vast experience in management, operations, business and strategic planning in the pharmaceutical industry, where he has held various senior positions over the years. Past positions include VP of Operations at Teva Pharmaceuticals’ API and Innovative divisions, where he was credited for his contribution to the market success of Teva; COO of Peptor Ltd; CEO of the Jerusalem-based biotechnology company, Gamida Cell, a leader in hematopoietic (blood) stem cell therapeutics; President and CEO of Makhteshim Chemical Works Ltd., followed by position of Senior VP of Supply Chain at Makhteshim-Agan Group. In addition to his role as Chairman & CEO at Stem Cell Medicine, Mr. Marom also acts as Chairman & CEO of Mapi Pharma.
Dr. Geffen has extensive experience in the areas of clinical and preclinical drug development. She served as CEO of Avraham Pharmaceuticals, a phase 2b clinical stage company developing drugs for Alzheimer’s disease, and VP R&D and Validation at Compugen Ltd (NASDAQ: CGEN). Dr. Geffen holds a Ph.D from the Department of Immunology and Microbiology and an M.Sc. in business management, both from the Ben-Gurion University, Israel.
Ms. Zalayet CPA serves as Stem Cell Medicine’s CFO as of 2012. Prior to this Ms. Zalayet served as deputy CEO of Kesselman & Kesselman Trust Co. (1971) Ltd. and as a CPA at PwC Israel. Irit completed her Bachelors in Economics and Accounting and her M.A. in Law; both degrees are from The Bar-Ilan University. Ms. Zalayet also serves as the CFO of a related group party Pharma Two B.
Dr. Hayden Ideses holds a PhD in Organic Chemistry from the Ben Gurion University in Beer Sheva, Israel. Past experience includes Makhteshim Chemical Works R&D Department as Team Leader, Teva API Division as QC Manager 1991-1995, Dexcel Pharma R&D QA Manager 1995-2002, Trima Pharmaceutical Industry – Quality Assurance Manager 2002-2016
Ms. Saciuk joined Stem Cell Medicine in 2019. Previously, she worked at the aerospace engineering industry in Asia where she served as Business Development Manager and founded a representative office in China. She received her BA in Philosophy and East Asia Studies from the Hebrew University and received an MA in Political Science from National Taiwan University. She is fluent in Mandarin Chinese.
Dr. Yudin has extensive experience in the areas of neuro-cell and molecular biology, developing stem cell-based therapeutic methods for the treatment of multiple sclerosis, critical limb ischemia and other diseases. He served on the R&D team at Gamida Cell, in the area of development of hematological transplants based on expanded cord blood stem cells. Dr. Yudin holds a PhD in Biological Chemistry from the Weizmann Institute Of Science, Rehovot, and a post-doctoral degree from Columbia University, New-York
Dr. Uzi received his PhD in Medical Research from the Hebrew University Hadassah Medical Center and specializes in cellular metabolism and toxicity, gene therapy and human disease models as platforms for stem cell therapy. Prior to joining Stem Cell Medicine, he served as VP and Head of Research and Development at Clearance Ltd, and as Human Disease Model Consultant at BiolineRx. Dr. Uzi has published his work in leading journals and as a main author in a leading hepatology textbook. He has also received the Israel Association for the Study of the Liver’s Award for Excellence twice.
Mr. Gomberg has extensive experience in the areas of formulation of pharmaceutical preparations and clinical pharmacology and advanced nursing care. He served as R&D Project Manager at Dexcel Pharma, where he worked in developing formulations of tablets and semi-solids and participated in patent writing and submission of clinical trial batches for Phase I, Phase II, and clinical trials of Bioequivalence studies. Mr. Gomberg holds a B.Pharm degree from the Hebrew University of Jerusalem
Mr. Ecker has extensive experience in analytical chemistry. He serves as the QC manager as of 2015. Prior to this he served as a team leader in the R&D department of Perrigo API. Mr. Ecker has a Bsc. In chemistry and a Msc. In Biochemistry, both from the Hebrew university.